P131 Phase I trial of the combination of the epigenetic modulators vorinostat and azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). An update from the NY Cancer Consortium

L. Silverman; A. Verma; R. Odchimar-Reissig; A. LeBlane; V. Najfeld; J. Gabrilove; L. Isola; I. Espinoza-Delgado; J. Zwiebel

doi:10.1016/S0145-2126(09)70212-7

P131 Phase I trial of the combination of the epigenetic modulators vorinostat and azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). An update from the NY Cancer Consortium

L. Silverman
, A. Verma
, R. Odchimar-Reissig
, A. LeBlane
, V. Najfeld
, J. Gabrilove
, L. Isola
, I. Espinoza-Delgado
, J. Zwiebel

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	S135-S136
Journal	Leukemia Research
Volume	33
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1016/S0145-2126(09)70212-7
State	Published - May 2009

Access to Document

10.1016/S0145-2126(09)70212-7

Cite this

Silverman, L., Verma, A., Odchimar-Reissig, R., LeBlane, A., Najfeld, V., Gabrilove, J., Isola, L., Espinoza-Delgado, I., & Zwiebel, J. (2009). P131 Phase I trial of the combination of the epigenetic modulators vorinostat and azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). An update from the NY Cancer Consortium. Leukemia Research, 33(SUPPL. 1), S135-S136. https://doi.org/10.1016/S0145-2126(09)70212-7

@article{8f791cf7b3c248cca8f53b284bd7305b,

title = "P131 Phase I trial of the combination of the epigenetic modulators vorinostat and azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). An update from the NY Cancer Consortium",

author = "L. Silverman and A. Verma and R. Odchimar-Reissig and A. LeBlane and V. Najfeld and J. Gabrilove and L. Isola and I. Espinoza-Delgado and J. Zwiebel",

year = "2009",

month = may,

doi = "10.1016/S0145-2126(09)70212-7",

language = "English",

volume = "33",

pages = "S135--S136",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd.",

number = "SUPPL. 1",

}

Silverman, L, Verma, A, Odchimar-Reissig, R, LeBlane, A, Najfeld, V , Gabrilove, J , Isola, L, Espinoza-Delgado, I & Zwiebel, J 2009, 'P131 Phase I trial of the combination of the epigenetic modulators vorinostat and azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). An update from the NY Cancer Consortium', Leukemia Research, vol. 33, no. SUPPL. 1, pp. S135-S136. https://doi.org/10.1016/S0145-2126(09)70212-7

P131 Phase I trial of the combination of the epigenetic modulators vorinostat and azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). An update from the NY Cancer Consortium. / Silverman, L.; Verma, A.; Odchimar-Reissig, R. et al.
In: Leukemia Research, Vol. 33, No. SUPPL. 1, 05.2009, p. S135-S136.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - P131 Phase I trial of the combination of the epigenetic modulators vorinostat and azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). An update from the NY Cancer Consortium

AU - Silverman, L.

AU - Verma, A.

AU - Odchimar-Reissig, R.

AU - LeBlane, A.

AU - Najfeld, V.

AU - Gabrilove, J.

AU - Isola, L.

AU - Espinoza-Delgado, I.

AU - Zwiebel, J.

PY - 2009/5

Y1 - 2009/5

UR - https://www.scopus.com/pages/publications/65349086724

U2 - 10.1016/S0145-2126(09)70212-7

DO - 10.1016/S0145-2126(09)70212-7

M3 - Article

AN - SCOPUS:65349086724

SN - 0145-2126

VL - 33

SP - S135-S136

JO - Leukemia Research

JF - Leukemia Research

IS - SUPPL. 1

ER -

Silverman L, Verma A, Odchimar-Reissig R, LeBlane A, Najfeld V , Gabrilove J et al. P131 Phase I trial of the combination of the epigenetic modulators vorinostat and azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). An update from the NY Cancer Consortium. Leukemia Research. 2009 May;33(SUPPL. 1):S135-S136. doi: 10.1016/S0145-2126(09)70212-7